Tradestie Institutional Equity Comparison Engine
RKTO vs PHIO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
PHIO Overall Edge
PHIO Captures Institutional Edge (3โ0 Pillars ยท 8โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Phio Pharmaceuticals Corp. Common Stock (PHIO) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, RKTO trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus PHIO at 0.3x Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, RKTO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against PHIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
PHIO
RKTO N/M vs PHIO 0.3x Fwd P/E
Growth & Margin Winner
PHIO
Op Margin N/A vs 0.0% ยท YoY N/A vs +0.0%
Momentum & Technical Winner
PHIO
1Y -82.5% vs -47.5% ยท 52W Pos 2% vs 1%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
RKTO
US Equity
RKTO
Institutional Equity
$0.30
+6.11% 1D
Market Cap
N/A
1M Return
-44.23%
1Y Return
-82.53%
Forward P/E
N/M
Unified AI Score
44.2 / 100
HOLD
Tech 45.0
Fund 42.0
Flow 50.0
Mom 55.0
PHIO
NASDAQ
Phio Pharmaceuticals Corp. Common Stock
Pharmaceutical Preparations
$0.66
-8.25% 1D
Market Cap
$8.5M
1M Return
-24.81%
1Y Return
-47.52%
Forward P/E
0.3x
Unified AI Score
41.2 / 100
SELL
Tech 25.0
Fund 46.0
Flow 50.0
Mom 59.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
RKTO -82.53%
PHIO -47.52%
Spread: +40.07 pp (PHIO Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
RKTO TTM Op. Margin: N/A
PHIO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RKTO vs PHIO. Trailing 12-month operating profitability (RKTO N/A vs PHIO 0.0%) and valuation multiples (RKTO N/M vs PHIO 0.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | RKTO | PHIO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $8.5M | Larger Scale | PHIO |
| Trailing P/E Ratio Valuation | N/M | 0.3x | Lower Multiple | PHIO |
| Forward P/E Ratio Valuation | N/M | 0.3x | Lower Multiple | PHIO |
| Revenue Growth (YoY) Growth | N/A | +0.0% | Higher Growth | PHIO |
| Operating Margin (TTM) Profitability | N/A | 0.0% | Higher Margin | PHIO |
| Net Profit Margin Profitability | N/A | 0.0% | Higher Margin | PHIO |
| Return on Equity (ROE) Capital Efficiency | N/A | -159.0% | Higher ROE | PHIO |
| 52-Week Range Position Momentum | 2% ($0โ$2) | 1% ($1โ$2) | Stronger Trend | Tie |
| Beta / 30D Volatility Risk Regime | 1.16ฮฒ ยท 63% Vol | 1.07ฮฒ ยท 57% Vol | Lower Realized Risk | PHIO |
| Unified Institutional Score Composite Signal | 44.2 / 100 (HOLD) | 41.2 / 100 (SELL) | Higher Composite | RKTO |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full RKTO vs PHIO Buy Guide
RKTO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
PHIO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither RKTO nor PHIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.